Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Aug;205(2):135.e1-9.
doi: 10.1016/j.ajog.2011.03.048. Epub 2011 Apr 8.

Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate

Tracy A Manuck  1 , Yinglei Lai, Paul J Meis, Mitchell P Dombrowski, Baha Sibai, Catherine Y Spong, Dwight J Rouse, Celeste P Durnwald, Steve N Caritis, Ronald J Wapner, Brian M Mercer, Susan M Ramin
Affiliations
Randomized Controlled Trial

Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate

Tracy A Manuck et al. Am J Obstet Gynecol. 2011 Aug.

Abstract

Objective: Seventeen-alpha-hydroxyprogesterone caproate (17-OHPC) reduces recurrent preterm birth (PTB). We hypothesized that single nucleotide polymorphisms in the human progesterone receptor (PGR) affect response to 17-OHPC in the prevention of recurrent PTB.

Study design: We conducted secondary analysis of a study of 17-OHPC vs placebo for recurrent PTB prevention. Twenty PGR gene single nucleotide polymorphisms were studied. Multivariable logistic regression assessed for an interaction between PGR genotype and treatment status in modulating the risk of recurrent PTB.

Results: A total of 380 women were included; 253 (66.6%) received 17-OHPC and 127 (33.4%) received placebo. In all, 61.1% of women were African American. Multivariable logistic regression demonstrated significant treatment-genotype interactions (either a beneficial or harmful treatment response) for African Americans delivering<37 weeks' gestation for rs471767 and rs578029, and for Hispanics/Caucasians delivering<37 weeks' gestation for rs500760 and <32 weeks' gestation for rs578029, rs503362, and rs666553.

Conclusion: The clinical efficacy and safety of 17-OHPC for recurrent PTB prevention may be altered by PGR gene polymorphisms.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Study enrollment
17P = 17-alpha hydroxyprogesterone caproate AA = African-American C/H = Caucasian or Hispanic
See this image and copyright information in PMC

References

    1. Swamy GK, Ostbye T, Skjaerven R. Association of preterm birth with long-term survival, reproduction, and next-generation preterm birth. JAMA. 2008;299:1429–36. - PubMed
    1. Porter TF, Fraser AM, Hunter CY, Ward RH, Varner MW. The risk of preterm birth across generations. Obstet Gynecol. 1997;90:63–7. - PubMed
    1. Esplin MS. Preterm birth: a review of genetic factors and future directions for genetic study. Obstet Gynecol Surv. 2006;61:800–6. - PubMed
    1. McManemy J, Cooke E, Amon E, Leet T. Recurrence risk for preterm delivery. Am J Obstet Gynecol. 2007;196:576 e1–6. discussion e6-7. - PubMed
    1. Schieve LA, Handler A. Preterm delivery and perinatal death among black and white infants in a Chicago-area perinatal registry. Obstet Gynecol. 1996;88:356–63. - PubMed

Publication types

MeSH terms

Substances

Grants and funding